IDH1 and glioblastoma: Recent studies on molecular pathology of glioma has outlined some valuable prognosis biomarkers such as IDH1, 1q-19p co-deletion, h3k27, TERT (Killela et al., 2014; Marton et al., 2019; Zhang Z. Y. et al., 2019), but the existed biomarkers still cannot fully predict the overall survival for all glioblastoma patients, such as IDH1 wild-type in WHO grade 2 gliomas or in recurrent gliomas; moreover, we know a little about of the MGMT demethylation status in glioma patients.